Studies including adult patients with HCC treated with PD-1-, PD-L1-, and/or CTLA-4-targeting ICIs before LT or after LT for recurrent HCC were eligible.<h4>Results</h4>Fifty-one studies were included. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.